novo nordisk pfizer - Search News

Pfizer sues Metsera, Novo Nordisk

Digest more

· 2h · on MSN

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

In late morning trade, the stock edged up by 1% in Copenhagen.

· 1h · on MSN

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

· 42m

Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats

· 20h

Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo

A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hear...

· 20h

Novo Nordisk and Pfizer Sweeten Their Offers for Weight-Loss Drug Startup Metsera

· 1d

Pfizer plays hardball in weight-loss drug fight

· 1d

Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid

The lawsuit targets Metsera’s controlling shareholders Arch Ventures and Validae Health, which Pfizer said “have conspired with Metsera and Novo Nordisk in furtherance of these anti-competitive activi...

· 20h

Novo Nordisk Hikes Metsera Bid to up to $10B in Competition With Rival Pfizer

Axios · 21h

Novo Nordisk and Pfizer raise bids for Metsera

Novo Nordisk's Medicare deal takes heat off Wegovy slowdown

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth slows, but investors cheered a better-than-expected Medicare pricing deal that helped lift the shares after an initial slide.

Devdiscourse

Legal Showdown: Pfizer and Novo Nordisk Clash Over Metsera in Fierce Obesity Drug Battle

Pfizer and Novo Nordisk are in a heated legal and bidding war over Metsera, an obesity drug developer. Novo's $10 billion bid challenges Pfizer's prior deal with Metsera. Pfizer has sued to stop the process,

BioSpace

Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say.But he said Pfizer was the best fit for Metsera.